Physician profile
Jack J Khouri
NPI 1851739668
$39,017.69
in general payments reported to CMS, 2019-2025
16 companies · $21K in 2025
The $21K reported for 2025 was more than what 89% of Medical Oncology providers received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,077 · 2020: $12.45 · 2022: $89.66 · 2023: $1,130 · 2024: $13K · 2025: $21K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $25K · Education: $6,197 · Food and Beverage: $2,383 · Travel and Lodging: $1,861.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $25,397.50 |
| Education | $6,197.00 |
| Food and Beverage | $2,383.25 |
| Travel and Lodging | $1,861.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kite Pharma, INC. | $8,879.38 | 2025 | Yescarta |
| Janssen Scientific Affairs, LLC | $7,694.66 | 2022-2025 | Darzalex, Tecvayli |
| Janssen Biotech, INC. | $6,929.26 | 2023-2025 | Tecvayli, Darzalex, Talvey |
| E.R. Squibb & Sons, L.L.C. | $6,098.00 | 2024 | Pomalyst |
| Legend Biotech USA INC. | $5,528.55 | 2024-2025 | Carvykti |
| Genzyme Corporation | $2,975.00 | 2019 | |
| Biolinerx USA, INC. | $178.40 | 2024 | Aphexda |
| Regeneron Healthcare Solutions, INC. | $144.37 | 2025 | Libtayo |
| Beigene USA, INC. | $139.17 | 2024 | Brukinsa |
| Pfizer INC. | $119.56 | 2025 | |
| Secura Bio, INC. | $101.50 | 2019 | |
| Seagen INC. | $99.00 | 2025 | |
| Abbvie INC. | $79.80 | 2024 | |
| Janssen Global Services, LLC | $38.59 | 2025 | |
| Karyopharm Therapeutics INC. | $12.45 | 2020 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jack Khouri listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.